{
    "id": 25306,
    "fullName": "BCL2L1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "BCL2L1 positive indicates the presence of the BCL2L1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 598,
        "geneSymbol": "BCL2L1",
        "terms": [
            "BCL2L1",
            "Bcl-X",
            "BCL-XL/S",
            "BCL2L",
            "BCLX",
            "PPP1R52"
        ]
    },
    "variant": "positive",
    "createDate": "09/07/2016",
    "updateDate": "06/12/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8173,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with JQ1 resulted in decreased expression of BCL2 and BCL2L1 in murine transgenic lymphoma cells over expressing MYC, subsequently leading to increased expression of BCL2L11 (Bim) and apoptotic activity in culture (PMID: 27406984).",
            "molecularProfile": {
                "id": 26187,
                "profileName": "BCL2 pos BCL2L1 pos BCL2L11 pos MYC over exp"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6567,
                    "pubMedId": 27406984,
                    "title": "BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27406984"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9016,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sensitivity to S63845 negatively correlated with BCL2L1 mRNA level in a panel of hematological cancer cell lines in culture (PMID: 27760111).",
            "molecularProfile": {
                "id": 26189,
                "profileName": "BCL2L1 positive"
            },
            "therapy": {
                "id": 4858,
                "therapyName": "S63845",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6851,
                    "pubMedId": 27760111,
                    "title": "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760111"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2074,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A-1155463 induced apoptosis in a BCL2L1 (BCL-XL)-dependent acute lymphocytic leukemia cell line in culture (PMID: 25787766).",
            "molecularProfile": {
                "id": 26189,
                "profileName": "BCL2L1 positive"
            },
            "therapy": {
                "id": 2576,
                "therapyName": "A-1155463",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2473,
                    "pubMedId": 25787766,
                    "title": "Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25787766"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9017,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sensitivity to S63845 negatively correlated with BCL2L1 mRNA level in a panel of solid tumor cell lines in culture (PMID: 27760111).",
            "molecularProfile": {
                "id": 26189,
                "profileName": "BCL2L1 positive"
            },
            "therapy": {
                "id": 4858,
                "therapyName": "S63845",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6851,
                    "pubMedId": 27760111,
                    "title": "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760111"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8182,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, murine transgenic lymphoma cells over expressing MYC in culture demonstrated resistance to treatment with JQ1 due to a BCL2L11 (Bim)-null background (PMID: 27406984).",
            "molecularProfile": {
                "id": 26191,
                "profileName": "BCL2 pos BCL2L1 pos BCL2L11 neg MYC over exp"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6567,
                    "pubMedId": 27406984,
                    "title": "BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27406984"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20153,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VU661013 and Navitoclax (ABT-263) combination treatment induced apoptosis and inhibited growth of estrogen receptor-positive breast cancer cell lines expressing BCL2, BCL2L1, and MCL1 in culture, and induced cell death and inhibited tumor growth in a cell line xenograft model (PMID: 31595181).",
            "molecularProfile": {
                "id": 34907,
                "profileName": "BCL2 pos BCL2L1 pos MCL1 pos"
            },
            "therapy": {
                "id": 9280,
                "therapyName": "Navitoclax + VU661013",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16725,
                    "pubMedId": 31595181,
                    "title": "Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31595181"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20151,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) and Navitoclax (ABT-263) combination treatment induced apoptosis and inhibited growth of estrogen receptor-positive breast cancer cell lines expressing BCL2 and BCL2L1 in culture, and inhibited mTORC1 signaling and tumor growth, and induced cell death in a cell line xenograft model (PMID: 31595181).",
            "molecularProfile": {
                "id": 34908,
                "profileName": "BCL2 pos BCL2L1 pos"
            },
            "therapy": {
                "id": 9279,
                "therapyName": "Everolimus + Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16725,
                    "pubMedId": 31595181,
                    "title": "Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31595181"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26187,
            "profileName": "BCL2 pos BCL2L1 pos BCL2L11 pos MYC over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26189,
            "profileName": "BCL2L1 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26191,
            "profileName": "BCL2 pos BCL2L1 pos BCL2L11 neg MYC over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28848,
            "profileName": "BCL2L1 pos TNFRSF10B pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34907,
            "profileName": "BCL2 pos BCL2L1 pos MCL1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34908,
            "profileName": "BCL2 pos BCL2L1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}